Sign up to access all valuation multiples
Founded in the 1880s and listing on the ASX in 1952, ALS operates three divisions: commodities, life sciences, and industrial. ALS commodities traditionally generated the majority of underlying earnings, providing geochemistry, metallurgy, inspection and mine site services for the global mining industry. Expansion into environmental, pharmaceutical and food testing areas and commodity price weakness have lessened earnings exposure to commodities.
1910
20.5K+
LTM Revenue $2.0B
LTM EBITDA $488M
$7.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ALS has a last 12-month revenue (LTM) of $2.0B and a last 12-month EBITDA of $488M.
In the most recent fiscal year, ALS achieved revenue of $1.9B and an EBITDA of $434M.
ALS expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ALS valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.0B | XXX | $1.9B | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $1.7B | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 90% | XXX | XXX | XXX |
| EBITDA | $488M | XXX | $434M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $347M | XXX | $273M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $215M | XXX | $165M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $915M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of September 5, 2025, ALS's stock price is AUD 19 (or $12).
ALS has current market cap of AUD 9.4B (or $6.0B), and EV of AUD 11.2B (or $7.2B).
See ALS trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.2B | $6.0B | XXX | XXX | XXX | XXX | $0.44 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of September 5, 2025, ALS has market cap of $6.0B and EV of $7.2B.
ALS's trades at 3.9x EV/Revenue multiple, and 18.8x EV/EBITDA.
Equity research analysts estimate ALS's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ALS has a P/E ratio of 28.0x.
See valuation multiples for ALS and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.0B | XXX | $6.0B | XXX | XXX | XXX |
| EV (current) | $7.2B | XXX | $7.2B | XXX | XXX | XXX |
| EV/Revenue | 3.6x | XXX | 3.9x | XXX | XXX | XXX |
| EV/EBITDA | 14.8x | XXX | 18.8x | XXX | XXX | XXX |
| EV/EBIT | 20.7x | XXX | 26.8x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 28.0x | XXX | 48.0x | XXX | XXX | XXX |
| EV/FCF | 44.6x | XXX | 48.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialALS's last 12 month revenue growth is 7%
ALS's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
ALS's rule of 40 is 28% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ALS's rule of X is 43% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ALS and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 20% | XXX | XXX | XXX |
| Rule of 40 | 28% | XXX | 28% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 43% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 76% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Sonic Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Bangkok Dusit Medical Services | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ALS acquired XXX companies to date.
Last acquisition by ALS was XXXXXXXX, XXXXX XXXXX XXXXXX . ALS acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was ALS founded? | ALS was founded in 1910. |
| Where is ALS headquartered? | ALS is headquartered in Australia. |
| How many employees does ALS have? | As of today, ALS has 20.5K+ employees. |
| Who is the CEO of ALS? | ALS's CEO is Mr. Malcolm Deane. |
| Is ALS publicy listed? | Yes, ALS is a public company listed on ASX. |
| What is the stock symbol of ALS? | ALS trades under ALQ ticker. |
| When did ALS go public? | ALS went public in 1952. |
| Who are competitors of ALS? | Similar companies to ALS include e.g. Australian Clinical Labs, Healius, Integral Diagnostics, Sonic Healthcare. |
| What is the current market cap of ALS? | ALS's current market cap is $6.0B |
| What is the current revenue of ALS? | ALS's last 12 months revenue is $2.0B. |
| What is the current revenue growth of ALS? | ALS revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of ALS? | Current revenue multiple of ALS is 3.6x. |
| Is ALS profitable? | Yes, ALS is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ALS? | ALS's last 12 months EBITDA is $488M. |
| What is ALS's EBITDA margin? | ALS's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of ALS? | Current EBITDA multiple of ALS is 14.8x. |
| What is the current FCF of ALS? | ALS's last 12 months FCF is $161M. |
| What is ALS's FCF margin? | ALS's last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of ALS? | Current FCF multiple of ALS is 44.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
